Citius Pharmaceuticals, Inc. Warrant
CTXRW
CTXRW was delisted on the 8th of August, 2022.
2 hedge funds and large institutions have $2K invested in Citius Pharmaceuticals, Inc. Warrant in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | +$3.63K | +15,871 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$20 | -86 | -42% |
|
CTXRW Hedge Fund Activity: Q2 2022 in Review
2 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals, Inc. Warrant (CTXRW) for Q2 2022, worth a combined $2K.
Buyers outnumbered sellers: 1 fund opened new CTXRW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $3.63K. The largest seller was UBS Group, cutting an estimated $20.
- 2 institutional investors held Citius Pharmaceuticals, Inc. Warrant (CTXRW) as of Q2 2022, up from 1 in Q1 2022.
- Funds reported $2K of Citius Pharmaceuticals, Inc. Warrant stock for Q2 2022.
- 1 fund opened new Citius Pharmaceuticals, Inc. Warrant positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest Citius Pharmaceuticals, Inc. Warrant buyer in Q2 2022 was Susquehanna International Group, an estimated $3.63K added.
- The largest Citius Pharmaceuticals, Inc. Warrant seller in Q2 2022 was UBS Group, an estimated $20 sold.
Based on aggregated 13F filings for Q2 2022.